Chemotherapeutics, on the one hand, has changed the concept of cancer treatment and on other hand causes various effects which increases morbidity of patients. Cisplatin is effective in treating oral cancers but associated electrolyte imbalance is the main concern.
Introduction
Platinum based chemotherapeutics like cisplatin, carboplatin, oxaliplatin, satraplatin, and picoplatin are in use for treating the solid organ malignancies since 1978 (1) . Platinum based chemotherapeutics induces apoptosis by cross linking DNA. Cisplatin, (cisplatinum, or cis-diamminedichloroplatinum) is the first class of platinum based chemotherapeutics, a known therapeutic option in multi-technique treatment of oral cancers (2) (3) (4) . Oral cavity and oropharynx malignancies are third most prevalent after stomach and cervical cancers, constitute around 2 to 5% of head and neck cancers (5) . Approximately, 450 000 new case of oral cancers reported in 2017 worldwide (6) . Bhurgri et al (Pakistan) reported 4.1 and 4 oral cancer cases per 100 000 population per year in males and females respectively (7) .
Platinum based chemotherapeutics have common side effects such as nephrotoxicity, neurotoxicity, ototoxicity, nausea, vomiting and electrolyte imbalance and myelosuppression principally like thrombocytopenia (1) . Side effects profile of carboplatin is better than cisplatin especially in children (8) . Early reports indicate that nephrotoxicity might occur in 50 to 75 % of patients receiving cisplatin (9) . However, reversible nephrotoxicity was generally noted between doses of 50 and 75 mg/ m 2 , while doses more than 100 mg/m 2 were frequently followed by acute renal failure in 47% of cases (10) .
Electrolyte imbalance is also quite common in cisplatin patients such as hypomagnesaemia (60%-90%), hypocalcaemia (70%-90%), hypokalemia (70%-95%) and hyponatremia (60%-80%) (9) . Injury to proximal tubules by cisplatin leads to decrease absorption and persistent excretion of magnesium, potassium and calcium (11) . Hence, the deranged renal function or electrolyte imbalance associated along with cisplatin therapy increases the morbidity and mortality of patients.
Objectives
Nephrotoxicity and electrolyte imbalance associated with cisplatin has a significant impact on patient's morbidity. Thus, its frequency determination in our population is important to reduce the burden of nephrotoxicity. This study aimed to determine the frequency of electrolyte imbalance associated with cisplatin in oral cancer patients.
Patients and Methods

Study population
This prospective study was conducted in oncology ward of Jinnah Postgraduate Medical Centre, over a period of 3 months (November 1, 2016 to May 7, 2017) . Oral cancer patients of either gender, more than 16 years of age and normal electrolytes before cisplatin therapy were included, whereas patients having derange renal function or abnormal electrolytes before cisplatin were excluded.
Those who fulfil the inclusion criteria were enrolled and informed consent was taken. All the demographic details (name, gender, age, occupation and education), clinical data (diagnosis) and therapeutic data (name of the drug, dose, route, frequency and duration of therapy) were collected from patients' records. Blood count, serum creatinine and blood urea nitrogen (BUN), serum electrolytes, urine electrolytes and albumin, analysis was conducted using VITROS Ortho-Clinical Diagnostics kits.
Before and after the completion of three cisplatin-based chemotherapy cycles, we assessed serum electrolytes, creatinine, BUN, urine protein, urine sodium, potassium and pH. Chemotherapy was given weekly, whereas concurrently radiotherapy with linear accelerator (6MV X-rays) in conventional fraction (1.8 Gy/fraction) was given once a day, 5 fractions per week using shrinking field technique. Each cycle of cisplatin 100 mg/m 2 at day 1, 07 and 22, after premedication with ondansetron 8 mg/IV stat, ranitidine 150 mg/IV, normal saline/IV 1000 mL before and after cisplatin therapy. The electrolyte imbalance associated with cisplatin will be assessed by measuring of pre-cisplatin and post-cisplatin cycle, of parameters such as sodium, potassium, calcium and magnesium.
Ethical considerations
This research was performed following the Declaration of Helsinki principles. Informed written consent was obtained from each patient. All information about individuals was coded and kept confidential. This study was approved by the institutional ethical committee and research oversight committee, Jinnah Post Graduate Medical Center, Karachi, Pakistan.
Statistical analysis
All the analysis will be conducted on Statistical Package for Social Sciences (SPSS) (Release 10.0, standard version). Mean ± standard deviation (SD) will be calculated for continuous variables like age, change in serum potassium, calcium, magnesium, sodium while, frequency distribution will be calculated for categorical variables like gender hypokalemia, hypocalcemia, hyponatremia and hypomagnesemia. Effect modifier will be controlled by stratification of age, controlling co-morbid conditions (diabetes and hypertension), weight, stage of the disease and premedication before cisplatin chemotherapy (IV fluids, antiemetics and antacids), using chi-square test.
Accordingly P values equal to or less than 0.05 will be considered as statistically significant. Table 1 ).
Results
Effects of cisplatin on serum electrolytes
Hypokalemia is observed in 90 (91.83%), percent decrease in potassium is -9.4%, and is more common in male than female, whereas hypocalcemia is reported in 87 (88.77%) of patients while percent decrease is -6.66% (hypocalcemia is more common in male). Hypomagnesemia is reported in 66 (67.34%) of patients (percent change is -7.18%), and hyponatremia was observed in 66 of cases (67.34%), while percent decrease was -3.35% (both are frequent in females than males) ( Tables 2, 3 and 4) . Stratification of age shows hypokalemia and hypocalcemia are more frequent among young and middle age group than older patients, whereas hyponatremia is frequent in older age patients and hypomagnesemia more frequent in younger patients (Table 5) .
Stratification according to type of oral cancer revealed that in squamous cell carcinoma, the most frequent electrolyte abnormality associated with cisplatin was hypokalemia (93.9%) and least common is hyponatremia (68.2%), whereas hypocalcemia (91.6%) is most common and hypomagnesemia (16.6%) is least common cisplatin associated electrolyte abnormality in verrucous type (Table 6) .
Stratification according to staging of oral cancer is given in Table 7 . Table 7 shows that in stage III, hypokalemia (94.6%) and hypomagnesemia (80.35%) are more frequent. In stage II, hypocalcemia (93.3%) is more frequent, whereas in stage IV, hyponatremia is the least frequent and the rest three are equally frequent (83.3%).
Discussion
This study was conducted to detect electrolyte imbalance after cisplatin cycles, thereby allowing supplementation of deficient electrolytes without disrupting the chemotherapy cycles.
Cisplatin is known for its effectiveness in the treatment of oral cancers, however, nephrotoxicity associated with cisplatin is reported for years. The exact mechanism has not been fully understood. It may increase membrane fragility and deplete intracellular glutathione while interacting with sulfhydryl compound. Additionally, cisplatin can induce apoptosis and necrosis of kidney cells in a dose dependent fashion. Cisplatin associated nephrotoxicity manifest clinically as rise in BUN, creatinine, disturbance in electrolytes and acute renal failure. Furthermore, cisplatin associated nephrotoxicity histologically manifests with acute focal tubular necrosis, convoluted tubule and collecting duct dilatation. The present study suggests that these changes must be reversible. At present, to avoid renal impairment and electrolyte imbalance, hydration and forced dieresis are administered as prophylaxis (12) .
In the present study, we observed hypokalemia (91.83%), hypocalcemia (87.75%), hypomagnesemia (67.34%) and hyponatremia (67.34%) after three cycles of cisplatin therapy (Table 2 ). In our study population, hypokalemia is the commonest electrolyte abnormality, observed in 90 patients (91.83%, P = 0.002). A significant decrease in potassium level was observed in males, especially in younger and middle age groups (Tables 3 and 4) , whereas Arunkumar et al (13) observed in 92% of their patients. Increased renal absorption capacity, in response to decreased absorption of intestinal potassium is a possible explanation behind it. Furthermore, magnesium and potassium are subjected to change in intestinal absorption and renal excretion with each cisplatin treatment (14) . Previous studies have suggested that cisplatin is known to produce hypokalemic paralysis (15) however, we had not paralysis in our study population.
Hypocalcemia is also quite common side effect of cisplatin chemotherapy. In our study population, 87 patients suffered from hypocalcemia (88.77%, P = 0.03; Table 2 ), whereas Arunkumar et al (13) found in 80% of their study population. Furthermore, in our observation both genders are significantly affected. Additionally hypocalcemia affects younger patients more as compared to others (Tables 3 and 4 ). The possible mechanism behind this complication is excessive urinary loss of calcium in urine, decreased renal tubular reabsorption of calcium due to tubular damage, due to low tissue response to parathormone, and low serum magnesium levels (16) . Electrolyte monitoring and continuous oral calcium substitution is advised for patients undergoing cisplatin therapy.
Hypomagnesemia is a well-known side effect of cisplatin treatment. In our study, 67.34% of patients developed this complication. Female suffer more as compared to male (66, P = 0.003; Tables 2 and 5 ), In contrast, Markman et al (17) reported the incidence of cisplatin-induced hypomagnesemia in 89% of ovarian cancer but their sample size was small. Direct injury to renal magnesium reabsorption in ascending loop of Henle, and distal tubule, is the possible mechanism behind the cisplatin-induced hypomagnesemia (18) .
Hyponatremia is not uncommon in patients on cisplatin chemotherapy. Renal salt wasting and syndrome of inappropriate antidiuretic hormone are possible mechanisms behind cisplatin-induced hyponatremia (19) . Cisplatin-induced hyponatremia was observed in 67.34 % (Tables 2 and 5) of our study population. Cisplatin-induced hyponatremia was more common in females and patients with older age group (Tables 3 and  4) . Hamdi et al (18) reported 69% incidence of cisplatininduced hyponatremia, on contrary Arunkumar et al (13) reported an increase in serum sodium level. They concluded that, opined that this may be due to infusing normal saline before cisplatin chemotherapy. Frequency and severity of cisplatin nephrotoxicity may be reduced by slow intravenous electrolyte infusions and maintaining the hydration, before, during and immediately after the administration of cisplatin
Conclusion
Our study concluded that electrolyte abnormalities are 
